These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review. Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713 [TBL] [Abstract][Full Text] [Related]
23. Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia. Yang F; Zong H; Li F; Luo S; Zhang X; Xu Y; Zhang X Platelets; 2023 Dec; 34(1):2135694. PubMed ID: 36281771 [TBL] [Abstract][Full Text] [Related]
24. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Neunert C; Despotovic J; Haley K; Lambert MP; Nottage K; Shimano K; Bennett C; Klaassen R; Stine K; Thompson A; Pastore Y; Brown T; Forbes PW; Grace RF; Pediatr Blood Cancer; 2016 Aug; 63(8):1407-13. PubMed ID: 27135461 [TBL] [Abstract][Full Text] [Related]
25. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics. Meyer O; Salama A Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379 [TBL] [Abstract][Full Text] [Related]
26. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres. Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125 [TBL] [Abstract][Full Text] [Related]
27. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag. Tarantino MD; Fogarty PF; Shah P; Brainsky A Platelets; 2015; 26(1):93-6. PubMed ID: 24433306 [TBL] [Abstract][Full Text] [Related]
28. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632 [TBL] [Abstract][Full Text] [Related]
29. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP]. Mori M; Kato M; Koh K; Hanada R Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675 [TBL] [Abstract][Full Text] [Related]
30. Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations. Cook L; Cooper N Drug Des Devel Ther; 2010 Jul; 4():139-45. PubMed ID: 20689640 [TBL] [Abstract][Full Text] [Related]
31. Eltrombopag for use in children with immune thrombocytopenia. Kim TO; Despotovic J; Lambert MP Blood Adv; 2018 Feb; 2(4):454-461. PubMed ID: 29487060 [TBL] [Abstract][Full Text] [Related]
32. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784 [TBL] [Abstract][Full Text] [Related]
33. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond. Taylor A; Westwood JP; Laskou F; McGuckin S; Scully M Br J Haematol; 2017 May; 177(3):475-480. PubMed ID: 28295201 [TBL] [Abstract][Full Text] [Related]
34. [Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia]. Horikoshi A; Tsukuda J; Abe R; Fujiwara N; Ito E; Takaku T Rinsho Ketsueki; 2016 May; 57(5):638-41. PubMed ID: 27263792 [TBL] [Abstract][Full Text] [Related]
35. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study]. Weber E; Moulis G; Mahévas M; Guy C; Lioger B; Durieu I; Hunault M; Ramanantsoa M; Royer B; Default A; Pérault-Pochat MC; Moachon L; Bernard N; Bardy G; Jonville-Bera AP; Geniaux H; Godeau B; Cathébras P Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553 [TBL] [Abstract][Full Text] [Related]
36. New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. Arnold DM; Nazi I; Kelton JG Expert Opin Investig Drugs; 2009 Jun; 18(6):805-19. PubMed ID: 19426124 [TBL] [Abstract][Full Text] [Related]
37. Thrombopoietin receptor agonists shift the balance of Fcγ receptors toward inhibitory receptor IIb on monocytes in ITP. Liu XG; Liu S; Feng Q; Liu XN; Li GS; Sheng Z; Chen P; Liu Y; Wei Y; Dong XY; Qin P; Gao C; Ma C; Zhang L; Hou M; Peng J Blood; 2016 Aug; 128(6):852-61. PubMed ID: 27281793 [TBL] [Abstract][Full Text] [Related]
38. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Kuter DJ Annu Rev Med; 2009; 60():193-206. PubMed ID: 19642221 [TBL] [Abstract][Full Text] [Related]
39. Eltrombopag for treatment of thrombocytopenia-associated disorders. Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898 [TBL] [Abstract][Full Text] [Related]